Tirzepatide, a once-weekly GIP/GLP-1 receptor agonist, is a medicine used for weight reduction in adults with obesity. A new analysis of the SURMOUNT clinical trials reveals that the medicine, ...

In the context of the global obesity epidemic, the FDA approved several glucagon-like peptide-1 (GLP-1) receptor agonists (GPL-1RAs), such as liraglutide (Saxenda) and semaglutide (Ozempic, Wegovy) as ...

Please provide your email address to receive an email when new articles are posted on . Adults with obesity and knee osteoarthritis had reductions in body weight and knee pain with retatrutide. More ...

A new once-a-month injection helped people with obesity shed up to 16% of their body weight, offering fresh hope for effective, long-acting treatments. Can this breakthrough change the landscape for ...